Credit Suisse Upgraded ResMed (RMD) to Neutral Following Q3 Results
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $224.46 -1.01%
Rating Summary:
11 Buy, 12 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 12 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Credit Suisse upgraded ResMed (NYSE: RMD) from Outperform to Neutral Friday morning following the company's Q3 results on Thursday afternoon.
Shares of ResMed are up more than 6 percent at last check.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed are up more than 6 percent at last check.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- Diana Shipping drops bid for Genco after price demands spike to $36.91
Create E-mail Alert Related Categories
UpgradesRelated Entities
Credit Suisse, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
